Results 11 to 20 of about 297,519 (217)
Transcutaneous Administration of Dengue Vaccines [PDF]
Viruses, 2020 In the present study, we evaluated the immunological responses induced by dengue vaccines under experimental conditions after delivery via a transcutaneous (TC) route.
Alves R P S +2 more
exaly +3 more sources
Dengue Vaccines: An Update. [PDF]
BioDrugs, 2022 Dengue is one of the most prevalent mosquito-borne diseases in the world, affecting an estimated 390 million people each year, according to models. For the last two decades, efforts to develop safe and effective vaccines to prevent dengue virus (DENV) infections have faced several challenges, mostly related to the complexity of conducting long-term ...
Torres-Flores JM +2 more
europepmc +3 more sources
Recent Developments in Recombinant Protein–Based Dengue Vaccines [PDF]
Frontiers in Immunology, 2018 Recombinant proteins are gaining enormous importance these days due to their wide application as biopharmaceutical products and proven safety record. Various recombinant proteins of therapeutic and prophylactic importance have been successfully produced ...
Nagesh K. Tripathi, Ambuj Shrivastava
doaj +2 more sources
A Multi-country Study of the Household Willingness-to-Pay for Dengue Vaccines: Household Surveys in Vietnam, Thailand, and Colombia [PDF]
PLoS Neglected Tropical Diseases, 2015 BACKGROUND:The rise in dengue fever cases and the absence of dengue vaccines will likely cause governments to consider various types of effective means for controlling the disease.
Thiem Vu +2 more
exaly +2 more sources
Dengue Virus and Vaccines: How Can DNA Immunization Contribute to This Challenge?
Frontiers in Medical Technology, 2021 Dengue infections still have a tremendous impact on public health systems in most countries in tropical and subtropical regions. The disease is systemic and dynamic with broad range of manifestations, varying from mild symptoms to severe dengue (Dengue ...
Ada Maria Barcelos Alves +2 more
exaly +3 more sources
Vaccines licensed and in clinical trials for the prevention of dengue
Human Vaccines and Immunotherapeutics, 2017 Dengue has become a major global public health threat with almost half of the world's population living in at-risk areas. Vaccination would likely represent an effective strategy for the management of dengue disease in endemic regions, however to date ...
J. Torresi, G. Ebert, M. Pellegrini
exaly +2 more sources
Frontiers in Immunology, 2021 The four serotypes of Dengue virus (DENV1-4) are arboviruses (arthropod-borne viruses) that belong to the Flavivirus genus, Flaviviridae family. They are the causative agents of an infectious disease called dengue, an important global public health ...
Luiz Wb +2 more
exaly +3 more sources
Dengue vaccines: the road to failure or to success? [PDF]
Human Vaccines & Immunotherapeutics, 2020 A licensed vaccine against dengue was shown to enhance disease under some circumstances, even though it protected most vaccinees. We discuss the implication of these results for the future of dengue vaccines.
Stanley A. Plotkin
doaj +2 more sources
PLoS Neglected Tropical Diseases, 2013 BackgroundA face-to-face survey of 158 policymakers and other influential professionals was conducted in eight dengue-endemic countries in Asia (India, Sri Lanka, Thailand, Vietnam) and Latin America (Brazil, Colombia, Mexico, Nicaragua) to provide an ...
Ole Wichmann, Richard T Mahoney
exaly +2 more sources
Development of Peptide Vaccines in Dengue [PDF]
Current Pharmaceutical Design, 2018 Dengue is one of the most important arboviral infections worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue serotypes that infect people living in South East Asia, where dengue is an endemic disease.
Magdalena Plebanski +2 more
exaly +3 more sources